Andrea Ellis Biography and Net Worth

Director of BridgeBio Pharma

Andrea Ellis has served as a member of our Board of Directors since August 2021. Mrs. Ellis is the Chief Financial Officer of Fanatics Betting & Gaming. Prior to joining Fanatics, Mrs. Ellis was the Chief Financial Officer of Lime, an innovative transportation technology company, and before that held various roles in finance, operations, and product management at Restaurant Brands International for many leading food chains. She previously spent six years at Goldman Sachs in investment banking and trading. Mrs. Ellis earned her bachelor’s degree from the University of Pennsylvania and a master’s degree in business administration from Harvard Business School.

What is Andrea Ellis' net worth?: The estimated net worth of Andrea Ellis is at least $394,560.00 as of April 1st, 2025. Ellis owns 12,000 shares of BridgeBio Pharma stock worth more than $394,560 as of April 9th. This net worth evaluation does not reflect any other investments that Ellis may own. Learn More about Andrea Ellis' net worth.
How do I contact Andrea Ellis?: The corporate mailing address for Ellis and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Andrea Ellis' contact information.
Has Andrea Ellis been buying or selling shares of BridgeBio Pharma?: Within the last three months, Andrea Ellis has sold $1,021,500.00 in shares of BridgeBio Pharma stock. Most recently, Andrea Ellis sold 30,000 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a transaction totalling $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company's stock, valued at $408,600. Learn More on Andrea Ellis' trading history.
Who are BridgeBio Pharma's active insiders?: BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Andrea Ellis (Director), Neil Kumar (CEO), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.
Are insiders buying or selling shares of BridgeBio Pharma?: In the last year, insiders at the sold shares 16 times. They sold a total of 15,548,828 shares worth more than $477,823,236.19. The most recent insider tranaction occured on April, 1st when Director Andrea Ellis sold 30,000 shares worth more than $1,021,500.00. Insiders at BridgeBio Pharma own 24.7% of the company. Learn More about insider trades at BridgeBio Pharma.
Information on this page was last updated on 4/1/2025.

Andrea Ellis Insider Trading History at BridgeBio Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/1/2025	Sell	30,000	$34.05	$1,021,500.00	12,000

Andrea Ellis Buying and Selling Activity at BridgeBio Pharma

BridgeBio Pharma Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $32.88

$28.33

$33.28

50 Day Range

MA: $33.55

$30.14

$37.22

2 Week Range

Now: $32.88

$21.62

$39.47

Volume

5,599,238 shs

Average Volume

2,249,322 shs

Market Capitalization

$6.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08